Bintrafusp alfa clinical trials
Also written M7824 and MSB0011359C.
How each study uses bintrafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bintrafusp alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2020 (16)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 9 |
| 2019 | 4 |
| 2020 | 16 |
| 2021 | 13 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 35
National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (10) · EMD Serono Research & Development Institute, Inc. (9) · Institut Bergonié (1) · Fundación GECP (1) · Merck KGaA, Darmstadt, Germany (1) · The University of Hong Kong (1) · Yonsei University (1)
Often tested with
Tested in the same studies.
Immunocytokine NHS-IL12 (3) · Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 (1) · CEA-MUC-1-TRICOM Vaccine CV301 (1) · Nogapendekin alfa inbakicept (1) · SX-682 (1) · Cisplatin (1) · Carboplatin (1) · Pimasertib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test bintrafusp alfa.
- Dec 2026Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaPhase 2 · National Cancer Institute (NCI)
- Jan 2027Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaPhase 2 · Institut Bergonié
- Feb 2027Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic CholangiocarcinomaPhase 1 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses bintrafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 46
- TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapYRecruitingNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT04481256Written as Bintrafusp alfaHow we know
- Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04417660Written as M7824How we know
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04235777Written as M7824How we know
- Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic CholangiocarcinomaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04708067Written as Bintrafusp AlfaHow we know
- Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaActive, not recruitingPhase 2Institut BergoniéNCT04874311Written as Bintrafusp alfaHow we know
- Combination Immunotherapy in Subjects With Advanced HPV Associated MalignanciesCompletedPhase 1/2National Cancer Institute (NCI)NCT04287868Written as M7824How we know
- Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04789668Written as Bintrafusp AlfaHow we know
- Bintrafusp Alfa Program Rollover StudyCompletedPhase 3EMD Serono Research & Development Institute, Inc.NCT05061823Written as Bintrafusp alfaHow we know
- Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural MesotheliomaCompletedPhase 2Fundación GECPNCT05005429Written as Bintrafusp alfaHow we know
- Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung CancerTerminatedPhase 2Mayo ClinicNCT04396535Written as Bintrafusp AlfaHow we know
- Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).CompletedPhase 2National Cancer Institute (NCI)NCT05012098Written as Bintrafusp alfa/M7824How we know
- Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus InfectionCompletedPhase 1/2National Cancer Institute (NCI)NCT04247282Written as M7824How we know
- Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT03315871Written as MSB0011359C (M7824)How we know
- Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal CancersCompletedPhase 2National Cancer Institute (NCI)NCT04491955Written as MSB0011359CHow we know
- M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)CompletedPhase 3EMD Serono Research & Development Institute, Inc.NCT03631706Written as M7824How we know
- Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)CompletedPhase 1/2National Cancer Institute (NCI)NCT04574583Written as M7824How we know
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03436563Written as Anti-PD-L1/TGFbetaRII Fusion Protein M7824How we know
- MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid TumorsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02699515Written as MSB0011359CHow we know
- Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04220775Written as Bintrafusp AlfaHow we know
- M7824 in Treating Patients With Stage II-III HER2 Positive Breast CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT03620201Written as Bintrafusp AlfaHow we know
See all 46 studies that test bintrafusp alfa →
Given beside what is tested · 10 — bintrafusp alfa is usual care or a partner of the new treatment
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT04633252Written as M7824How we know
- PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT04303117Written as M7824How we know
- A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04708470Written as Bintrafusp AlfaHow we know
- HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04432597Written as M7824How we know
- First in Human Study of M6223CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT04457778Written as Bintrafusp alfaHow we know
- Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedPhase 1/2National Cancer Institute (NCI)NCT03493945Written as M7824How we know
- M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT03554473Written as M7824How we know
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Written as Bintrafusp alfaHow we know
- N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerWithdrawnPhase 2National Cancer Institute (NCI)NCT05445882Written as Bintrafusp alfaHow we know
- Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT04551950Written as M7824How we know
Codes
What other systems call bintrafusp alfa · ClinicalTrials.gg INT017419
- UNII (FDA) NW9K8C1JN3BINTRAFUSP ALFAOne source FDA
- NCI Thesaurus C124229Bintrafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NW9K8C1JN3 | BINTRAFUSP ALFA | One source FDA |
| NCI Thesaurus | C124229 | Bintrafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.